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Abstract: Within the chronic obstructive pulmonary disease (COPD) spectrum, lung emphysema 
presents, as a primarily histopathologic feature, the destruction of pulmonary   parenchyma and, 
accordingly, an increase in the airflow obstruction distal to the terminal bronchiole. No  twithstanding 
the significant advances in prevention and treatment of symptoms, no effective or curative therapy 
has been accomplished. In this context, cellular therapy with stem cells (SCs) arises as a new 
th  erapeutic approach, with a wide application potential. The   purpose of this study is to e  valuate the 
safety of SCs infusion procedure in patients with advanced COPD (stage IV dyspnea). After selec-
tion, patients underwent clinical examination and received granulocyte colony-stimulating f  actor, 
immediately prior to the bone marrow harvest. The bone marrow mononuclear cells (BMMC) 
were isolated and infused into a peripheral vein. The 12-month follow-up showed a significant 
improvement in the quality of life, as well as a clinical stable condition, which suggest a change in 
the natural process of the disease. Therefore, the proposed methodology in this study for BMMC 
cell therapy in sufferers of advanced COPD was demonstrated to be free of significant adverse 
effects. Although a larger sample and a greater follow-up period are needed, it is possible to infer 
that BMMC cell therapy introduces an unprecedented change in the course or in the natural history 
of emphysema, inhibiting or slowing the progression of disease. This clinical trial was registered 
with ClinicalTrials.gov (NCT01110252) and was approved by the Brazilian National Committee 
of Ethics in Research (registration no. 14764, CONEP report 233/2009).
Keywords: cell therapy, chronic obstructive pulmonary disease COPD, pulmonary e  mphysema, 
BMMC, stem cells
Introduction
Chronic obstructive pulmonary disease (COPD) may be defined as a pathological state 
characterized by gradual, chronic, and nonreversible airflow impairment. This limitation 
is associated with the abnormal inflammatory response of the lungs to the inhalation 
of particles and/or toxic gases. The main symptoms associated with the pathology are 
chronic and progressive dyspnea and productive cough.1,2
COPD is a public health problem worldwide, with high prevalence and si  gnificant 
e  conomic and social impact.2–5 According to recent World Health O  rganization data, the 
global prevalence of COPD was estimated to be approximately 210 million i  ndividuals, 
with 80   million ranking among the moderate and/or severe stage of the disease. Currently, 
it is the fifth chief cause of death; however, estimates put it in the third rank by 2030, 
primarily due to exposure to risk factors, especially to cigarette smoke.1
Within the COPD spectrum, the most relevant feature in the lung emphysema is 
airflow limitation, resulting from the loss of alveolar wall and enlargement of alveolar International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
64
Ribeiro-Paes et al
space distal to the terminal bronchiole.1,2,6,7 In spite of the 
advances in the prevention and treatment of the s  ymptoms, 
no effective therapy has been accomplished till now. None 
of the advancements has enabled the reduction of the disease 
progression. 
Considering all these aspects, the e  pidemiological data 
and the social impact associated with this pathological condi-
tion, several experimental models have been proposed aiming 
to increase the knowledge of the physiopathological processes 
and expand the options for COPD treatment.2,8–18
In this context, cellular therapy (CT) with stem cells (SCs) 
arises as a new therapeutic approach, with a wide applica-
tion potential. A wide range of literature exists indicating 
promising results and therapeutic outlooks with adult and 
embryonic SCs for organ regeneration and repair, including 
pulmonary tissue.16–27
Notwithstanding the lack of consistent data on the SC 
h  oming mechanism, a set of experimental evidence has upheld 
the likelihood of using mesenchymal stem cells or a bone 
m  arrow mononuclear cells (BMMC) pool to treat chronic 
lung diseases. For this purpose, several studies report the 
migration of adult (mesenchymal and hematopoietic) SCs 
to injured areas in lungs, which regenerate the pulmonary 
parenchyma.16–26
This evidence, along with other supporting information, 
have served as basis for proposing a protocol for the use of 
cell therapy in lung diseases. Therefore, this study has sought 
to evaluate the safety of the procedure of SCs infusion in 
patients with advanced COPD (stage IV dyspnea).
Patients and methods
Patient selection
This study was carried out at the Cardiovascular Diseases 
Institute in São José do Rio Preto, São Paulo, Brazil, from 
May 2009 to October 2009. Four patients (as approved by 
the Brazilian National Committee of Ethics in Research 
[CONEP], Brazil) with clinical and laboratory diagnosis 
of advanced pulmonary emphysema were enrolled in 
this study. Patients signed the Knowledge and Free Con-
sent Instrument (TCLE) after receiving oral and written 
information that the procedure entailed possible risks 
and benefits. The clinical protocol, as well as the TCLE, 
developed for this study was registered with CONEP (reg-
istration no. 14764) in 2008. It was approved in April 2009 
(report no. 233/2009) for application in 4 of a total of 10 
patients requested in the original project sent to CONEP. 
The protocol has also been registered with ClinicalTrials.
gov (NCT01110252).
Inclusion criteria were as follows: aged between 40 and 
72 years, severe COPD, limited life expectancy, ineffective 
clinical treatments, limitation in daily physical activities, 
acceptable nutritional condition, acceptable cardiac func-
tion, satisfactory psychosocial and emotional profile and 
family support, possibility of pulmonary rehabilitation 
physiotherapy, and no tobacco use for at least 6 months 
before the protocol application, besides scoring higher than 
3 according to the Modified Medical Research Council 
(MRC) Dyspnea Scale Score test.28,29
Exclusion criteria were as follows: active pulmonary 
or extrapulmonary infection, serious coronaropathy and/
or ventricular dysfunction, significant renal illness and/or 
hepatitis, detected immunosuppressive illnesses, smoking 
habit, carrier of known neoplasias, pregnancy, lack of family 
support, psychosocial problems, drug or alcohol abuse, and 
noncompliance with established medical protocol.
Clinical evaluation and complementary 
laboratory tests in the preprocessing 
phase
In the preprocessing phase, patients underwent a complete 
evaluation of the pulmonary function with bronchodilator, 
cardiopulmonary test I, determination of residual volume and 
pulmonary diffusion capacity, cardiac evaluation (clinical 
examination, echocardiography, and   electrocardiography), 
chest X-ray, chest computed tomography scan (helical/high 
resolution), scintigraphic ventilation/  perfusion, as well as 
routine laboratory tests (blood gas, urinalysis,   coagulation, 
complete blood count (CBC), blood urea nitrogen, f  asting 
glucose, creatinine, C-reactive protein, serology for hepatitis 
B and C, antihuman immunodeficiency virus, and trepone-
mal test for syphilis (FTA-ABS)). The Dyspnea Scale Score 
test, modified according to the British MRC, was also con-
ducted, according to Mahler and Wells28 and Curley.29
stimulation with g-CsF
Patients received a dose of granulocyte colony-stimulating 
factor (G-CSF) (Filgrastin™; Laboratório Aché, Guarulhos, 
São Paulo, Brazil) at 5 µg/kg by   subcutaneous injection 
(13 × 4.5 needle) in the back of the arm for three consecu-
tive days before the bone marrow harvest to stimulatie the 
production and release of hematopoietic SCs, as reported 
by Koca and Champlin.30
harvest of sCs
Patients were taken to the operating room, placed in a prone 
position, and administered a spinal anesthesia. During the International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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whole procedure, the individuals were maintained on nasal 
oxygen catheter (2 L/min) and monitored (pulse oximeter, 
blood pressure, and electrocardiogram).
A total of 20 (10 on each iliac crest) punctures was 
made, always in different parts, with a Jamshidi needle 
(Pharmaseal™; Baxter Healthcare Corporation, Valencia, 
CA). Approximately, 10 mL of bone marrow were aspi-
rated from each puncture, using a 20-mL syringe previ-
ously filled with 0.5 mL of heparin sodium (5000 IU/mL) 
(Roche; Rio de Janeiro, Brazil). The collected material 
was added to a Baxter™ (Baxter Healthcare Corpora-
tion) collection bag. The clamps of the collection kit were 
opened and the bone marrow total content was filtered by   
gravity.
Preparation of the sCs
The collection bag packed in a sterile field was opened 
inside a laminar flow hood. The collection bag content was 
collected with the aid of a coupler, in strictly aseptic condi-
tions. Inside the laminar flow, 20 mL of Ficoll-Hypaque 
Premium™ (GE Healthcare, Uppsala, Sweden) were placed 
in polypropylene centrifuge tubes of 50 mL (Corning™; São 
Paulo, Brazil) and then 30 mL of bone marrow (diluted 1:1 
with saline) were added, to give a total a volume of 50 mL 
inside the tube with the Ficoll-Hypaque Premium solution. 
Afterward, the tubes were centrifuged at 300 g for 30 min 
at 18°C.
The ring of mononuclear cells formed above the 
Ficoll layer was collected with the aid of a sterile Pasteur 
pipette. Then, the mononuclear cells were transferred to 
other 50 mL centrifuge tubes. The volume was completed 
with RPMI c  ulture medium (Cultilab, Campinas, Brazil). 
These tubes were centrifuged at 300 g for 15 min at 18°C. 
After   centrifugation, the supernatant was discarded. The 
precipitate was r  esuspended in RPMI culture medium. The 
contents of all the tubes were aggregated and then centri-
fuged at 300 g at 18°C for 10 min. At the end of this step, 
the precipitate was resuspended to a final volume of ∼50 mL 
with albumin saline solution (ASS) aiming for two param-
eters: volume (50 mL) and final concentration of 1 × 108 
mononuclear cells/mL. The total volume was filtered in a 
Cell Strainer™ (BD Falcon, San Jose, CA) with a p  orosity 
of 100 µm to remove any impurities, cellular aggregates, 
and/or bone fragments.
Two counts with Turk’s solution and trypan blue were 
performed: the first count after the collection of bone 
marrow and the second count after the processing of the 
cells.
sCs infusion
The infusion was made into a (medial brachial) peripheral vein, 
promptly after the preparation, separation, and counting of the 
mononuclear cells. The mononuclear cells (BMMC) pool solu-
tion, diluted in physiological serum at 5% albumin (ASS) to a 
final volume of 30 mL, was slowly infused, over ∼20 min. The 
study design of this clinical trial is s  chematically presented in   
Figure 1.
Clinical progress
Consultations and clinical-ambulatory follow-ups were 
scheduled for a total of six appointments for tests conduc-
tion and analysis of the patients’ clinical progress, as shown 
in Table 1.
The schedule as shown in Table 2 was followed, except 
for those conditions in which a specific clinical evaluation 
recommended making urgent examinations.
statistical analysis
The project originally sent to the National Committee of 
Ethics in Research (CONEP-Brazil) demanded an initial 
sample of 10 patients. This sample size would allow a statis-
tical analysis by using nonparametric tests (Wilcoxon test). 
However, the protocol was approved for the study of only 
Study design
Patient selection
MRC higher than 3
Harvest of stem cells from bone marrow
BMMC isolation
Platelets
BMMC
Ficoll-Hypaque
Erythrocytes
Stem cells infusion
Figure 1 study design adopted for this unicentric clinical trial of cellular therapy in 
chronic obstructive pulmonary disease – pulmonary emphysema.
Abbreviations: BMMC, bone marrow mononuclear cells; MRC, Modified Medical 
Research Council [Dyspnea scale].International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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four patients. Given the smaller sample size, the originally 
proposed test could not be conducted.
Results
The age of selected patients ranged from 59 to 76 years, and 
all were males with advanced COPD (stage IV dyspnea). 
Smoking habit for at least 20 years was a common feature for 
all patients, and furthermore, all had quit smoking 10 years 
ago. All cases reported dyspnea at minimum exertions and 
chronic O2 dependence by nasal catheter. Table 3 shows in 
summary the general data of the four patients submitted to 
the BMMC infusion procedure.
Generally speaking, the laboratory parameters were 
consistent with clinical normality and acceptability. The 
chief results which lead to conclusions and extrapolations 
are shown and discussed. The results of echocardiogram 
analysis of patients IMC 001, IMC 002, and IMC 003 
did not show serious impairment of systolic and diastolic 
functions; only patient IMC 004 showed a mild degree of 
mitral insufficiency. Likewise, the results of electrocardio-
gram analysis did not show significant changes. Comput-
erized tomography validated the diagnoses of moderate 
and advanced pulmonary emphysema, with centrilobular 
being the predominant type, and occurrence of calcified 
pulmonary nodules.
Patient IMC 001 showed signs and symptoms due to the 
use of G-CSF, such as fever, nausea, indisposition, and small 
discomfort. After the BMMC pool infusion, no adverse reac-
tions occurred that could be associated with cell therapy.
The partial results from spirometry analysis before and 
after the CT infusion are shown in Figures 2–4.
Patient IMC 001 showed improved clinical condi-
tion and a gradually reduced O2 intake by nasal catheter 
immediately after the procedure. However, in the long 
term, the progress was severely harmed by several com-
plications, which were neither linked to the procedure nor 
presented by the other patients. Unquestionably, clinical 
and laboratory parameters showed that this patient had 
the most serious and advanced COPD condition. These 
continuous complications impaired the patient’s progress 
and clinical follow-up. Some tests could not be conducted 
in this patient and, therefore, the laboratory results are not 
shown in the results.
The arterial blood gas tests carried out before and 30 days 
after the procedure are shown in Table 4. The achieved results 
do not allow a precise analysis of the patients’   possible 
laboratory improvement. Other than the small sample size 
of four patients, there are complications with respect to the 
arterial blood gas tests, such as the infection acquired by 
patient IMC 001 and the conduction of gas analysis without 
O2 by patient IMC 003.
All patients received stimulation with the use of G-CSF 
in order to increase the number of SCs in the bone marrow. 
The hemogram analysis before and after the three doses of 
G-CSF showed a significant increase in the number of cells 
for all patients (data not shown). As this comparative analy-
sis d  emonstrates, the increase in leucocytes may lead to an 
increase in young, undifferentiated cells, which proportion-
ally decreases CD133+ cells and/or makes them undetectable 
(Table 5).
Table 2 Clinical and complementary examinations in the postprocedure phase
Clinical and laboratorial parameters Time in relation to the procedure date
7 days 1 month 2 months 3 months 6 months 12 months
Visit for clinical evaluation × × × × × ×
Complete ventilation test with bronchodilator × × × × ×
Chest X-ray × × ×
Chest CT ×
scintigraphy: inhalation/perfusion ×
Arterial blood gases × × ×
CBC × × × × × ×
CeA (tumor marker) ×
6-min walking test (cardiopulmonary test I) × × × × ×
Dyspnea scale score × × × × × ×
Abbreviations: CT, computed tomography; CBC, complete blood count; CeA, carcinoembryonic antigen.
Table 1 Patients’ follow-up: laboratory tests frequency in relation 
to procedure date
• Visit 1–7 days • Visit 4–3 months
• Visit 2–1 month • Visit 5–6 months
• Visit 3–2 months • Visit 6–12 monthsInternational Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Discussion
The COPD cell therapy reported in this study refers to a 
Phase I clinical protocol. Its chief purpose was to evaluate 
the safety of the procedure. Even though the small approved 
sample size (four patients) does not allow for a reliable 
statistical analysis, inferences may be drawn in connection 
with relevant aspects, other than safety, such as the proce-
dure efficacy and the incorporation of other methodological 
approaches.
By taking into account the accomplished results and the 
patients’ clinical progress, it may be asserted that the method-
ology at issue for the collection and infusion of BMMC free 
of collateral effects. This important affirmation is essential 
for continuing and/or increasing the number of patients in 
future protocols, which may also address the introduction of 
new methodological approaches, such as the infusion form 
of the BMMC pool (directly into the pulmonary tissue), the 
increase of the bone marrow volume to be collected, and the 
infusion in repeated doses.
All the voluntary subjects showed improvement in their 
clinical condition. The complete reports suggest a greater time 
tolerance without O2 intake by nasal catheter, besides a greater 
capacity on exertion, without significant fall in saturation. The 
fact that this sensation of clinical improvement may be due to 
a mere placebo effect may not be excluded, which would eas-
ily explain the patient’s response during the first days or even 
weeks after treatment; however, it would not justify the results 
after several months of laboratory and clinical follow-up.
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Table 3 general data of the procedures in the first four patients submitted to cell therapy for advanced pulmonary emphysema with 
pool of BMMC
Patients Sex Age 
(years)
COPD 
score
Procedure 
date
G-CSF 
stimulation
Bone marrow  
harvested volume (mL)
Infusion (BMMC) 
volume (mL)
Venous access
IMC 0011 M 76 IV 11/05/09 3 days 151 30 Brachial
IMC 002 M 64 IV 07/07/09 3 days 200 30 Brachial
IMC 003 M 59 IV 13/08/09 3 days 200 30 Brachial
IMC 004 M 64 IV 01/10/09 3 days 202 30 Brachial
Note: 1Patient presented continuous complications (repeated infections) that impaired the long-term clinical follow-up.
Abbreviations: BMMC, bone marrow mononuclear cells; COPD, Chronic Obstructive Pulmonary Disease; g-CsF, granulocyte colony-stimulating factor; M, male.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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The spirometry results from patients IMC 002, IMC 003, 
and IMC 004 indicate a very slight improvement, as shown 
in Figures 2–4. The results and analysis of patient IMC 001 
were probably impaired by the unfavorable   clinical progress, 
arising out of a spate of complications, such as pneumonia and 
infection. However, all the patients, especially patients IMC 
002 and IMC 003, showed a significant i  mprovement in their 
psychological condition and quality of life.
Patient IMC 002 is worth a special analysis, because his 
clinical response was the most successful. He prolonged his 
walking distance and walking time without important dyspnea. 
He reported a significant recovery with pronounced improve-
ment in his quality of life and psychological condition. An 
extremely relevant aspect is the need to include a question-
naire to compare between the quality of life before and after 
the procedure.
The FEV 1 laboratory analysis showed an improvement in 
all patients after 30 days. Later, patient IMC 002 presented a 
progressive decrease, which was associated to a condition of 
airways infection (Figure 2). There was continuation of the 
values of patient IMC 003 and a considerable improvement 
in IMC 004. Likewise, the increase in forced vital capacity 
(FVC) and vital capacity (VC) parameters was verified in all 
patients after 30 days following procedure (Figures 3 and 4); 
however, after this period, FVC decreased. An important 
aspect refers to the values which were constantly higher 
than the values found before the procedure. Only patient 
IMC 002 showed a sharper decrease in the values during 
examination as a result of his infectious clinical condi-
tion, and he presented changes in connection with the VC 
parameter. Generally speaking, the evaluated parameters 
demonstrate laboratory improvement and infer the possibility 
of alveolar regeneration without change in the pulmonary 
tissue elasticity.
The preliminary results of this clinical study   suggest 
that the procedure must be completed in a less advanced 
stage of pulmonary emphysema. This is upheld by previous 
work. Voltarelli et al31 made a   prospective study in 15 newly 
  diagnosed patients with type 1   diabetes   mellitus in the 
asymptomatic stage (,6 weeks). The patients were submit-
ted to the   autologous n  onmyeloablative hematopoietic SC 
transplantation. The results showed that, of the 15 patients 
who underwent the treatment, 14 patients became insulin-
free for a period and only one patient did not respond to the 
therapy. Other work has also demonstrated that the use of 
SCs in the treatment of several pathologies, such as rheu-
matic illness, lupus nephritis, systemic lupus erythematosus, 
ovarian cancer, multiple sclerosis, Hodgkin’s disease, and 
myocardiopathies, has shown greater effectiveness when 
SC therapy is instituted in patients in less advanced stages 
of the disease.32–39
According to the National Agency of Sanitary Surveillance 
(ANVISA RDC resolution 153/2004),40 the total blood vol-
ume to be aspirated from bone marrow cannot exceed 9 mL/
kg of body weight for men and 8 mL/kg of body weight for 
women. In compliance with this resolution, from a 70-kg male 
patient, for example, a bone marrow volume of up to 630 mL 
could be collected. In this study, the collected volume from 
each patient ranged from 150 to 200 mL. CD133+ cells were 
only detected in patient IMC 003, precisely the patient who 
presented, according to data in Table 2, the highest NC number 
and highest BMMC recovery. By virtue of the very restricted 
sample size, these data do not allow a definite conclusion, but 
they advance the possibility that the bone marrow volume to 
be collected should be considerably higher than that adopted in 
this protocol. Therefore, the proposition for harvesting a higher 
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Figure 4 Vital capacity (VC) pre- and postprocedure.
Table 4 Results of arterial blood gases tests pre- and postprocedure
IMC 001 IMC 002 IMC 003 IMC 004 Benchmarks
Pre Post Pre Post Pre Post1 Pre Post
PaCO2 (mm hg) 81 45 39 41 35 52 40 37 36–46
PaO2 (mm hg) 51 65 60 58 97 45 68 60 80–100
O2 content (%) 82 92 91 90 98 83 94 92 92–96
Note: 1Without nasal oxygen catheter.
Abbreviations: PaCO2, ; PaCO, .International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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bone marrow volume is based on the above considerations, that 
is: 1) the feasibility and safety of collecting a higher volume of 
material, as carried out in hematopoietic SC transplantation, 
and 2) the logical inference that a higher aspirated bone marrow 
volume results, proportionally, at the end of the process and 
adult SC separation in a significant higher number of CD133+ 
cells. Therefore, this item should be reviewed and possibly 
changed in future studies.
It is important to emphasize, in the bone marrow source 
autologous therapy, that G-CSF, a hematopoietic growth 
factor which stimulates the proliferation and mobilization of 
bone marrow hematopoietic cells to the peripheral blood,41–45 
has been used in cell therapy procedures in both animal and 
human models.46–51 The rationale for its use in this study was 
related to previous results showing that this drug determines 
an increase in myeloid progenitor cells and CD34+ cells.41,52 
However, as can be seen in Table 3, G-CSF did not induce 
the proliferation of cell lines CD34+ and CD133+, which are 
possibly involved in the regeneration of damage tissues.53–55 
Therefore, its application may be dispensed upon attaining 
cells with direct bone marrow puncture.
The results obtained indicate that the methodology used 
for BMMC pool cell therapy in emphysema patients is quite 
safe, without any significant adverse effects and/or that could 
mean a risk to patients. The laboratory analysis, confirmed 
by clinical response, reported a slight improvement in all 
patients, chiefly in the first 30 days after the procedure was 
carried out. After this period, laboratory tests displayed a 
tendency to decrease; however, they did not drop to the 
base values obtained before the BMMC therapy. These 
results indicate the possibility that cell therapy may be 
applied long term for the purpose of stimulating pulmonary 
regeneration.
Considering the small sample size of patients, the 
results do not support definite conclusions, but they pro-
vide indications and allow the postulation of the need for 
new alternatives and methodological adjustments in the 
adopted protocol. Among the proposals for methodological 
adjustment that may be considered in future studies, the fol-
lowing should be included: a questionnaire to analyze the 
patients’ quality of life; increasing the bone marrow volume 
to be harvested (300–400 mL); omitting the use of G-CSF 
as an inducer of cell proliferation and feasibility of chronic 
therapeutics through repeated doses; changing the inclusion 
criteria, by enrolling patients with less advanced pulmonary 
emphysema.
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